<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271777</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-210-6</org_study_id>
    <secondary_id>2010-023219-32</secondary_id>
    <nct_id>NCT01271777</nct_id>
  </id_info>
  <brief_title>Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy of GFT505 (80mg) Orally Administered Once Daily for 8 Weeks on Insulin Sensitivity Using a Glucose Clamp Technique and Safety in Male Patients With Insulin Resistance and Abdominal Obesity. A Multicentre, Randomised, Single Blind, Placebo-Controlled, Cross Over Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at
      80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be
      made using a glucose clamp technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per patient is 26 weeks: a selection period will precede a 8-week treatment
      period, a 6-week wash out period, a second 8-week treatment period in the second arm of
      treatment and a 2- week follow-up period.

      Schedule:

        -  Selection visit prior to treatment period (D-14 and D-1)

        -  D0 : randomisation visit

        -  Period T1: first period of treatment with GFT505 80mg or placebo for 8 weeks (D1 to D56)

        -  Wash out period for 6 weeks (D57 to D98)

        -  Period T2: second period of treatment with GFT505 80mg or placebo for 8 weeks (D99 to
           D154)

        -  Follow up period for 2 weeks (D155 to D169)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Infusion Rate (GIR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate in each patient the differences in Glucose Infusion Rate (GIR) measured at the end of 8 weeks treatment periods with GFT505 (80 mg/day per os) or placebo according to a cross-over design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in Hepatic Glucose Production (HGP) in each patient</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate in each patient the differences in Hepatic Glucose Production (HGP) measured at the end of 8 weeks treatment periods with GFT505 (80 mg/day per os) or placebo according to a cross-over design.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in GIR (Glucose Infusion Rate)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To compare the changes from baseline to endpoint in Glucose Infusion Rate (GIR). The baseline will be defined as the values of glucose clamp at V2. The same baseline will be used for the 2 periods. End-points will be defined as glucose clamp values at V4 for the first period and as glucose clamp values at V7 for the second period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HGP (Hepatic Glucose Production)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To compare the changes from baseline to endpoint in Hepatic Glucose Production (HGP). The baseline will be defined as the values of glucose clamp at V2. The same baseline will be used for the 2 periods. End-points will be defined as glucose clamp values at V4 for the first period and as glucose clamp values at V7 for the second period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Abdominal Obesity</condition>
  <arm_group>
    <arm_group_label>GFT505 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 80mg</intervention_name>
    <description>hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast</description>
    <arm_group_label>GFT505 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>hard gelatin capsules, oral administration, 4 capsules per day before breakfast</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Waist circumference ≥94cm.

          -  Body Mass Index ≤ 45kg/m2.

          -  Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) &gt; 3.

        Exclusion Criteria:

          -  Blood Pressure &gt; 160 / 95 mmHg.

          -  Diabetes mellitus 1 or 2.

          -  Historical of bariatric surgery.

          -  Patient treated with a lipid-decreasing medication.

          -  A fasting plasma triglycerides concentration &gt; 400mg/dL or a plasma Low Density
             Lipoprotein Cholesterol (LDL-c)concentration &gt; 220mg/dL.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy Hanf, Development Director</last_name>
    <role>Study Director</role>
    <affiliation>Genfit, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertrand CARIOU, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Nantes, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site n°1</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°2</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-diabetes</keyword>
  <keyword>Clamp technique</keyword>
  <keyword>PPARs</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

